SeqLL Inc
OTC:ATLN
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
SeqLL Inc
OTC:ATLN
|
227.9m USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.2T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
215.9B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
154.2B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
81T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
36B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
271B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37.5B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.9B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.5B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
SeqLL Inc
Glance View
SeqLL, Inc. engages in the design, development, and manufacture of genetic analysis technologies. The company is headquartered in Woburn, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-08-27. The company offers ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing solutions. The company uses its true single molecule sequencing (tSMS) technology. SeqLL offers RNA and specialty DNA sequencing services utilizing tSMS. SeqLL offers a range of RNA sequencing services, including its direct RNA sequencing without conversion to complementary DNA (cDNA). The firm operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies. Its testing services are fully customizable to customers research needs and challenges. Its SeqLL technology is used for various application, such as life sciences research and development, liquid biopsy, clinical diagnostics and microbiome analysis. The tSMS platform offers a sample preparation process.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for SeqLL Inc is -22.7%, which is above its 3-year median of -2 333%.
Over the last 3 years, SeqLL Inc’s Net Margin has increased from -3 746.5% to -22.7%. During this period, it reached a low of -15 626% on Mar 31, 2023 and a high of -8.7% on Mar 31, 2024.
